$7.54-2.0%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 5, 2026
Company outlook: revenue of $205M to $215M for Fiscal year 2026 — up 13.1% on a year earlier
The quarter ending September 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $45.9M | $41.6M | +10.14% |
| Profit | -$13.8M | -$25.6M | +45.85% |
| Profit per share | -$0.09 | -$0.18 | +50.00% |
| Free Cash Flow | $4.5M | -$18.1M | +124.85% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“Our second quarter results reflect the continued execution of our strategy and the momentum we are building across the business,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics and novel vaccines and to support research on human diseases. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world's leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Maravai LifeSciences Holdings, Inc.’s Item 2.02 8-K filed August 6, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Maravai LifeSciences Holdings, Inc.’s own guidance, from its results release of August 6, 2026. It is the company’s statement of what it expects, not a forecast of ours.
Maravai LifeSciences Holdings, Inc. reported on November 4, 2026. We are fetching the call transcript; its summary follows once the transcript is in.